Skip to main content
SpringerLink
Log in

Effects of recombinant interleukin 2 on immunological effector cells of the peripheral blood in patients with HBe antigen-positive chronic hepatitis

  • Original Article
  • Published:
Gastroenterologia Japonica Aims and scope Submit manuscript

Summary

Changes in peripheral blood immunological effector cells after systemic administration of recombinant interleukin 2 (rIL2) were studied in 14 patients with HBe antigen-positive chronic hepatitis. The patients were intravenously injected with rIL2 for 4 weeks, and the experiments were performed using mononuclear cells isolated from the peripheral blood during and after rIL2 administration. No significant changes in OKT4-positive cell population, OKT8-positive cell population, OKT4/OKT8 ratio and Leu7-positive cell population were detected during and after intravenous injection of rIL2. However, the natural killer (NK) cell and lymphokine-activated killer (LAK) cell activities significantly increased in the fourth week of rIL2 administration, while the K cell activity in the antibody-dependent cell-mediated cytotoxicity reaction, antibody response, lectininduced lymphocyte transformation and IL1 production of LPS-stimulated monocytes were not affected. These results suggest that IL2 increases the NK cell and LAK cell activitiesin vivo.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Farrar JJ, Benjamin WR, Hilfiker ML, et al: The biochemistry, biology, and role of interleukin 2 in the induction of cytotoxic T cell and antibody-forming B cell responses. Immunol Rev 1982; 63:129–166

    Article  PubMed  CAS  Google Scholar 

  2. Andrew ME, Churilla AM, Malek TR, et al: Activation of virus specific CTL clones: Antigen-dependent regulation of interleukin 2 receptor expression. J Immunol 1985; 134:920–925

    PubMed  CAS  Google Scholar 

  3. Rosenstein M, Yron I, Kaufmann Y, et al: Lymphokineactivated killer cells: Analysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. Cancer Res 1984; 44:1946–1953

    PubMed  CAS  Google Scholar 

  4. Domzig W, Stadler BM, Herberman RB: Interleukin 2 dependence of human natural killer (NK) cell activity. J Immunol 1983; 130:1970–1973

    PubMed  CAS  Google Scholar 

  5. Lanier LL, Benike CJ, Phillips JH, et al: Recombinant interleukin 2 enhanced natural killer cell-medicated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens. J Immunol 1985; 134:794–801

    PubMed  CAS  Google Scholar 

  6. Rosenberg SA, Lotze MT, Muul LM, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with metastatic cancer. N Engl J Med 1985; 313:1485–1492

    Article  PubMed  CAS  Google Scholar 

  7. Rosenberg SA, Spiess P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233:1318–1321

    Article  PubMed  CAS  Google Scholar 

  8. Rouse BT, Miller LS, Turtinen L, et al: Augmentation of immunity to herpes simplex virus byin vivo administration of interleukin 2. J Immunol 1985; 134:926–930

    PubMed  CAS  Google Scholar 

  9. Lotze MT, Frana LW, Sharrow SO, et al:In vivo administration of purified human interleukin 2:1. Half-life and immunologic effect of the Jurkat cell line-derived interleukin 2. J Immunol 1985; 134:157–166

    PubMed  CAS  Google Scholar 

  10. Rouse BT, Miller LS, Turtinen L, et al: Augmentation of immunity to herpes simplex virus byin vivo administration of interleukin 2. J Immunol 1985; 134:926–930

    PubMed  CAS  Google Scholar 

  11. Yamamoto S, Mizoguchi Y, Kuroki T, et al: A clinical trial of interleukin-2 treatment on HBe antigen-positive chronic hepatitis. In: Oda T, Okuda K, eds. New trends in hepatology, Medical Tosho Co, Ltd, Tokyo. 1986; 80–89

    Google Scholar 

  12. Hinuma S, Onda H, Naruo K, et al: Translation of interleukin 2m RNA from human peripheral blood leukocytes in Xenopus oocytes. Biochem Biophys Res Commun 1982; 109:363–369

    Article  PubMed  CAS  Google Scholar 

  13. Ortaldo JR, Mason AT, Gerald JP, et al: Effects of natural and recombinant IL2 on regulation of IFN-gamma production and natural killer activity: Lack of involvement of the TAC antigen for these immunoregulatory effects. J Immunol 1984;133:779–783

    PubMed  CAS  Google Scholar 

  14. Kato K, Naruo K, Koyama M, et al: Purification and partial sequence analysis of human interleukin-2 derived from peripheral blood leukocytes. Biochem Biophys Res Commun 1985; 127:182–190

    Article  PubMed  CAS  Google Scholar 

  15. Perlamnn P and Holm G: Cytotoxic effects of lymphoid cellsin vitro. Adv Immunol 1969; 11:117–185

    Article  Google Scholar 

  16. Jerne NK and Nordin AA: Plaque formation in agar by single antibody-producing cells. Science 1963; 140:405

    Article  Google Scholar 

  17. Stötter H, Rüde E, Wagner H: T cell factor (interleukin 2) allowsin vivo induction of T helper cells against heterologous erythrocytes in athymic (nu/nu) mice. Eur J Immunol 1980; 10:719–722

    Article  PubMed  Google Scholar 

  18. Hefeneider SH, Conlon PJ, Henney CS, et al:In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells. J Immunol 1983; 130:222–227

    PubMed  CAS  Google Scholar 

  19. Chang AE, Hyatt CL, Rosenberg SA: Systemic administration of recombinant human interleukin 2 in mice. J Biol Response Mod 1984; 3:561–572

    PubMed  CAS  Google Scholar 

  20. Lanier LL, Benike CJ, Phillips JH, et al: Recombinant interleukin 2 enhanced, natural killer cell-mediated cytotoxicity in human lymphocyte subpopulation expressing the Leu 7 and Leu 11 antigens. J Immunol 1985; 134:794–801

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Third Department of Internal Medicine, Osaka City University Medical School, 1-5-7 Asahi-machi, Abeno-ku, 545, Osaka, Japan

    Yasuhiro Mizoguchi M.D., Tokan Shin, Yoshihide Sakagami, Shuichi Seki, Tetsuo Kuroki & Kenzo Kobayashi

  2. First Department of Biochemistry, Osaka City University Medical School, 545, Osaka, Japan

    Seiji Morisawa

  3. Osaka Socio-Medical Center Hospital, 557, Osaka, Japan

    Sukeo Yamamoto

Authors
  1. Yasuhiro Mizoguchi M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tokan Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yoshihide Sakagami
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shuichi Seki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tetsuo Kuroki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kenzo Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sukeo Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Seiji Morisawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mizoguchi, Y., Shin, T., Sakagami, Y. et al. Effects of recombinant interleukin 2 on immunological effector cells of the peripheral blood in patients with HBe antigen-positive chronic hepatitis. Gastroenterol Jpn 23, 147–152 (1988). https://doi.org/10.1007/BF02799026

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02799026

Key Words

Search

Navigation